

Comparison of conbercept With Ranibizumab for the treatment of macular edema secondary to Branch Retinal Vein Occlusion (BRVO)

% R M X Q = K D R
Shandong University, China

Purpose:To confirm the therapeutic efficacy of the novel anti-VEGF reagent of Conbercept for the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

Methods:In this prospective, randomized, comparative study, patients were randomized and divided into Conbercept (n=18) and Ranibizumab (n=17) groups. After an initial intravitreal injection of either Conbercept or Ranibizumab, a pro re nata (PRN) strategy was adopted based on loss of visual acuity (VA) or increase in central macular thickness (CMT).

Results: